Biotech Values

[vinmantoo]

MRSN craters some 80% today on failure to meet primary endpoint in platinum resistant ovarian cancer, announces strategic reorganization. Ouch! IMGN shareholders know a bit how that felt a few years ago when the Forward 1 trial meet its primary end point. The difference was that after the fact data analysis showed that high alpha foliate receptor expressing patients showed efficacy with Elahare. That was borne out in the SORAYA & MIRASOL trials. However, avenue doesn't seem like a possibility for MRSN as the NaPi2b positive patients, the target for their ADC, looked similar to the general population in their trial.

https://finance.yahoo.com/news/mersana-therapeutics-announces-topline-data-110600082.html